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Abstract The purpose of this investigation was to assess the
real-life effectiveness of pegylated interferon (peg-IFN) α-2b
with ribavirin (RBV) in a cohort of treatment-naïve patients
with chronic genotypes 2 (G2) or 3 (G3) hepatitis C virus
(HCV) infection. A post-hoc pooled analysis of two Canadian
multicenter, observational studies, RediPEN and PoWer, was
carried out. A total of 1242 G2- or G3-infected patients were
included. The primary outcome was sustained virologic re-
sponse (SVR). Secondary endpoints included early virologic
response (EVR), end-of-treatment (EOT) response, and re-
lapse. Multivariate logistic regression was used to identify
independent predictors of treatment response. SVR in G2
and G3 was 74.4 % and 63.6 %, respectively. Relapse
occurred in 12.7 % and 19.1 % of G2- and G3-infected
patients achieving EOT response, respectively. Overall, G3
was found to independently predict reduced SVR [odds ratio
(OR) = 0.20; p= 0.007] and increased relapse (OR=6.84;
p=0.022). Among G3-infected patients, increasing fibrosis
score was the most important factor predicting reduced SVR
[F2 vs. F0/F1 (OR = 0.41; p = 0.009); F3 vs. F0/F1
(OR=0.72; p=0.338); F4 vs. F0/F1 (OR=0.27; p=0.001)].
Male gender (OR=13.16; p=0.020) and higher fibrosis score
[F2 vs. F0/F1 (OR = 9.72; p = 0.016); F3/F4 vs. F0/F1
(OR=4.23; p=0.113)] were associated with increased relapse
in G3 patients. These results support the real-life effectiveness
of peg-IFN α-2b plus ribavirin in HCV G2- and G3-infected
patients. Overall, genotype was identified as the most signif-
icant predictor of treatment outcome. Fibrosis score and gen-
der were key outcome predictors in the G3-infected popula-
tion. In clinical settings, peg-INF/RBVoffers an alternative for
patients without access to all oral direct-acting antivirals.
Introduction
According to the World Health Organization (WHO), 2–3 %
of the world’s population is currently infected with the hepa-
titis C virus (HCV) [1]. The epidemiology of HCV is highly
variable, with prevalence in individual countries ranging from
<1% to >10 % [2]. In 2013, the prevalence of HCV in Canada
was estimated at 251,990 viremic individuals, with the highest
number of cases occurring in the 40–54 years age group [3].
Genotypes 1 (G1; 64.1%), 2 (G2; 14.1%), and 3 (G3; 20.2%)
account for over 98 % of cases. Overall, approximately 8000
new cases are diagnosed each year, of which an estimated 70–
80 % will progress to chronic infection [4, 5]. Moreover, the
reported cases are likely an underestimate of the true incidence
of HCV infection, as a majority of acute HCV infections are
asymptomatic and, therefore, go undetected [6].
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Due to similar rates of viral decline and significantly higher
rates of sustained virologic response (SVR) compared with
G1 infections, G2 and G3 have traditionally been considered
a homogeneous entity, grouped together in efficacy analyses
[7]. However, evidence has emerged supporting the differen-
tiation of G2 and G3 in terms of clinical presentation and
response to treatment. Several reports have indicated that pa-
tients infected with G3 experience higher rates of steatosis and
bile duct lesions than their non-G3-infected counterparts
[8–10], with steatosis more significantly reduced by treatment
among patients infected with G3 than in other genotypes [8].
Furthermore, although still higher than in G1-infected pa-
tients, pegylated interferon-α (peg-IFN α) + ribavirin dual
combination therapy (PEG/RBV) in patients infected with
G3 has been associated with lower rates of SVR and higher
rates of relapse compared to those observed in patients infect-
ed with G2 [7, 11–17].
Up until recently, European and North American treatment
guidelines have dictated first-line PEG/RBV combination
therapy in both G2- and G3-infected patients [18–20]. How-
ever, based on the results of recent phase III trials [21–23],
Canadian and US recommendations have shifted focus to
sofosbuvir (SOF), an HCV polymerase inhibitor, in combina-
tion therapy with ribavirin as the first-line treatment of G2 and
G3 [24, 25]. Despite the promise of SOF-containing treatment
regimens, the cost of SOF is a significant barrier preventing
universal access. Moreover, the results of several recent cost
effectiveness analyses have shown that, despite high rates of
SVR, lower treatment duration, and a lower incidence of ad-
verse events, the incremental cost-effectiveness ratio (ICER)
of SOF-based treatments at their current cost, when compared
to PEG/RBV, exceed willingness-to-pay (WTP) thresholds of
up to $100,000 USD [26–29].
By evaluating, in a large cohort of treatment-naïve, chronic
G2 or G3 HCV-infected patients followed in Canadian routine
clinical care, we sought to clarify the real-life effectiveness of
PEG/RBV for the treatment of G2 and G3. Furthermore, we
identified genotype-specific predictors of response to
treatment.
Methods
This was a post-hoc analysis of two Canadian open-label,
multicenter, observational studies, the PEGETRON® Pro-
spective Optimal Weight-Based Dosing (OW-BD) Response
Program (PoWer) and the PEGETRON® REDIPEN®
Prospective OW-BD Response Program (RediPEN).
PoWer
The PoWer program was designed to prospectively assess
the real-world SVR rate (defined as HCV RNA
undetectable at 24 weeks from the end of treatment) in
Canadian HCV patients of all genotypes receiving
weight-based ribavirin plus peg-IFN α-2b (PEGETRON®
OW-BD). Enrolment took place between December 2002
and August 2005, to a total of 2250 patients. Eligible
patients included treatment-naïve adults (>18 years of
age), with chronic HCV infection, who were eligible as
per the PEGETRON® product monograph for treatment
with weight-based ribavirin plus peg-IFN α-2b, and were
able to obtain reimbursement for their treatment. Patients
were excluded if they had any of the PEGETRON product
monograph dictated contraindications pertaining to: hyper-
sensitivity to any interferons, ribavirin, or any component
of the injection and/or capsule; pregnant women or males
with pregnant female partners; patients with autoimmune
hepatitis or a history of autoimmune disease; patients with
a history of or a pre-existing severe psychiatric condition;
patients with a pre-existing thyroid abnormality; patients
with severe renal dysfunction; patients with decompensated
liver disease; epileptic patients; patients with a history of
severe or unstable pre-existing cardiac disease; patients
with hemoglobinopathies. Treatment was as per the
PEGETRON® product monograph and the standard of
care at each individual participating site. PEGETRON®
(peg-IFN α-2b) powder for solution was administered sub-
cutaneously at a dosage of 1.5 mcg/kg/week using plastic
disposable syringes, whereas PEGETRON® (ribavirin)
capsules (200 mg/capsule) were administered orally twice
daily with morning and evening meals. The dose of
PEGETRON® (ribavirin) capsules to be used in combina-
tion with PEGETRON® (peg-IFN α-2b) powder for solu-
tion was based on the patient body weight: patients
<64 kg were prescribed a daily dose of 800 mg of riba-
virin (four capsules total; two morning, two evening), pa-
tients 64 to <85 kg were prescribed a daily dose of
1000 mg of ribavirin (five capsules daily; two morning,
three evening), and patients >85 kg were prescribed a
daily dose of 1200 mg of ribavirin (six capsules daily;
three morning, three evening). The recommended treat-
ment duration was one year, with duration tailored to
baseline disease characteristics, response to therapy, and
tolerance of the regimen. However, a stopping rule was
implemented for patients for whom a virologic response
(undetectable HCV RNA) had not occurred by 6 months
of treatment, as it was deemed unlikely to occur after this
time. Recommended patient assessments were at baseline,
end-of-treatment (EOT), as well as 24 weeks following the
last dose of the study drug. The primary effectiveness
outcome measure of the study was the SVR rate at
24 weeks post-therapy. In addition, EOT response (defined
as undetectable HCV RNA at EOT) and relapse (defined
as detectable HCV RNA levels within 24 weeks after
achieving EOT response) were also evaluated.
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RediPEN
The RediPEN study assessed the real-world effectiveness of
weight-based ribavirin plus peg-IFN α-2b (PEGETRON®
OW-BD), administered with the REDIPEN® delivery system,
in Canadian patients of all genotypes with chronic HCV in-
fection. Additional objectives included the assessment of the
dropout rate and the rate of treatment discontinuation due to an
adverse event. Eligibility criteria were consistent with those in
PoWer, with the exception that patients were treated with
PEGETRON® REDIPEN™ and that HBsAg-positive pa-
tients, human immunodeficiency virus (HIV)-positive pa-
tients, and liver transplant recipients were not eligible for en-
rolment. In all, 1302 patients were enrolled in RediPEN from
July 2005 to June 2008. Treatment was per the PEGETRON®
product monograph and the standard of care at each individual
participating site. PEGETRON® (peg-IFN α-2b) powder for
solution was administered subcutaneously at a dosage of 1.5
mcg/kg/week using the REDIPEN® Single-dose Delivery
System, and equivalent weight-based algorithms for ribavirin
dosing, as previously described for PoWer, were applied. The
treatment duration was 24 or 48 weeks, and was to be indi-
vidualized as per the judgment of the treating physician based
on the baseline disease characteristics, response to therapy,
and tolerance of the regimen. However, as in PoWer, a
24-week stopping rule was implemented if virologic response
had not been achieved. Recommended patient assessments
were at baseline, week 12, EOT (24 or 48 weeks), and
24 weeks following the last dose of the study drug. Effective-
ness outcome measures included: early virologic response
(EVR; defined as either a >2 log decrease in HCV RNA from
baseline or as undetectable HCV RNA between weeks 10 and
14), EOT response, SVR, and relapse.
All patients provided informed consent before any study-
related procedure, and both PoWer and RediPEN were con-
ducted as per Good Clinical Practices and the tenets of the
Declaration of Helsinki. Ethics approval was obtained by a
central Institutional Review Board and local committees, as
required for each participating site.
Pooled analysis
For the purpose of the current post-hoc analysis, concerned
with treatment response to PEG/RBV in G2 and G3
HCV-infected patients, the pooled results of both studies in
the overall (ITT) and per genotype (G2 and G3) populations
are reported. In accordance with the exclusion of
HBsAg-positive, HIV-positive, and liver transplant patients
from RediPEN, patients in PoWer with these conditions were
excluded from the current analysis. As a result, the overall ITT
population consisted of 1242 patients, including
468 G2-infected (n=298 originating from PoWer, n=170
from RediPEN) and 774 G3-infected (n= 431 originating
from PoWer, n=343 fromRediPEN) individuals. The primary
effectiveness measure was SVR, while secondary outcomes
were EVR (available for RediPEN patients only), EOT re-
sponse, and relapse. Adverse events leading to treatment dis-
continuation were also assessed (RediPEN patients only).
Given that virologic response data at week 4 were not collect-
ed in either study, analysis of rapid virologic response (RVR)
was not possible. The following parameters were examined as
potential predictors of SVR and relapse: genotype, gender,
age, race, weight, Metavir fibrosis score, baseline viral load,
and geographic region. In addition, the association of fibrosis
score and EVR and EOT response was also assessed. Patients
lost to follow-up or with missing EVR, EOT response, and
SVR information were considered as non-responders.
In the current analysis, descriptive statistics were produced
for all variables. For continuous variables, these included the
mean, median, minimum, maximum, as well as the standard
deviation (SD), while frequency distributions were used for
categorical variables. Between-group differences in continu-
ous variables were assessed for statistical significance with the
Wilcoxon rank-sum test, while the Pearson chi-squared or
Fisher’s exact test, as required, were used for categorical var-
iables. Determinants of response to treatment were assessed
using univariate logistic regression. Variables that showed a
statistical trend (p<0.150) in the univariate analysis were con-
sidered in multivariate analysis to identify independent pre-
dictors of response. All analyses were conducted using SAS
9.2 (SAS Institute, Cary, NC).
Results
Study patients
Among the 1242 patients included in the ITT population, 468
(37.7 %) were infected with G2 and 774 (62.3 %) were infect-
ed with G3. Table 1 summarizes the number of patients in-
cluded in each analysis, as well as the number discontinuing
treatment prematurely. A total of 190 (15.3 %) individuals
were discontinued, with comparable rates between genotypes
(G2: 14.3 %; G3: 15.8 %). The reason for discontinuation was
missing for the majority of patients (collected in RediPEN
only); the predominant reasons for discontinuation included
adverse events (ITT: n=34; G2: n=15; G3: n=19), loss to
follow-up (ITT: n=23; G2: n=5; G3: n=18), and patient
choice (ITT: n=11; G2: n=3; G3: n=8).
The patient characteristics are provided in Table 2. Infor-
mation regarding age, gender, and race was available for
RediPEN patients only. The mean (SD) age of the ITT popu-
lation was 45.4 years (10.1), where the majority of patients
(58.5 %) were between the ages of 40 and 54 years. The
majority of patients were male (62.0 %), Caucasian
(82.3 %), and weighed in excess of 75 kg (59.7 %). In
Eur J Clin Microbiol Infect Dis (2016) 35:597–609 599
descending order, patients were enrolled primarily in Ontario
(46.8 %), followed by British Columbia (20.6 %), the Prairie
provinces (15.1 %), Quebec (14.7 %), and Atlantic Canada
(2.7 %). No remarkable differences were observed between
genotypes, with the exception of age, which was higher in
G2-infected patients (49.6 vs. 43.4 years).
Regarding disease parameters (Table 2), the mean (SD)
baseline HCV RNA levels were 6.2 (6.5) log10 IU/mL in the
ITT population, 6.3 log10 IU/mL (6.6) in the G2-infected pop-
ulation and 6.1 log10 IU/mL (6.4) in the G3-infected popula-
tion. Among patients with available Metavir fibrosis stage
(ITT: n=432; G2: n=185; G3: n=250), F0/F1 were the pre-
dominant stages (34.5 %, 38.9 %, and 31.2 % in the ITT, G2-,
and G3-infected populations, respectively), followed by F2
(30.8 %, 31.4 %, and 30.4 %, respectively), F3 (20.4 %,
19.4 %, and 21.2 %, respectively), and F4 (14.3 %, 10.3 %,
and 17.2 %, respectively). Treatment duration was predomi-
nantly for 24 weeks in the ITT, G2, and G3 populations
(78.8 %, 80.6 %, and 77.8 %, respectively).
Effectiveness
The EVR rate, assessed in RediPEN only (n=513), was 17.3 %
(n=89), 18.2 % (n=31), and 16.9 % (n=58) in the ITT, G2-,
and G3-infected populations, respectively. EOT response was
achieved in 79.1 % of ITT (n=982), 82.5 % of G2- (n=386),
and 77.0%ofG3-infected patients (n=596), and SVR in 67.6%
(n=840), 74.4 % (n=348), and 63.6 % (n=492) of patients,
respectively (Table 3). Relapse occurred in 16.6 % (n=163) of
patients in the ITT population achieving EOT response, and in
12.7 % (n=49) and 19.1 % (n=114) of G2- and G3-infected
patients achieving EOT response, respectively (Table 4). SVR
and relapse were assessed in the ITT, G2-, and G3-infected pop-
ulations per gender, race, weight, baseline viral load, geographic
location, and fibrosis score. EVR and EOT response were also
assessed per genotype per fibrosis score.
Subgroup analysis
Figure 1 illustrates the results of the genotype per fibrosis
score analysis for EVR, EOT response, SVR, and relapse.
Overall, a trend towards improved SVR (Fig. 1c) and relapse
(Fig. 1d) was observed in G2-infected patients compared to
G3-infected patients. Similarly, patients with low fibrosis
showed a better response to treatment, although the impact
of fibrosis stage was more evident in patients infected with
G3 compared to patients infected with G2 (Fig. 1a–d). Signif-
icant associations were observed between fibrosis stage and
SVR (F0/F1: 73.1 % vs. F2: 52.6 % vs. F3: 66.0 % vs. F4:
41.9 %; p=0.003) and relapse rate (F0/F1: 8.1 % vs. F2:
37.7 % vs. F3/F4: 21.8 %; p<0.001) in patients with G3
infection but not those with G2 infection.
Table 1 Patient disposition
ITT population (n= 1242) Genotype 2 (n= 468) Genotype 3 (n= 774)
n (%) n (%) n (%)
Included in EVR analysisa 513 (41.3) 170 (36.3) 343 (44.3)
Included in EOT analysis 1242 (100.0) 468 (100.0) 774 (100.0)
Included in SVR analysisb 1242 (100.0) 468 (100.0) 774 (100.0)
Included in relapse analysis 982 (79.0) 386 (82.4) 596 (77.0)
Discontinued 190 (15.3) 67 (14.3) 123 (15.8)
Reasons for discontinuationa,c
Adverse event 34 (17.9) 15 (22.4) 19 (15.4)
Lack of virologic response 2 (1.1) 0 (0.0) 2 (1.6)
Assigned shorter therapy 1 (0.5) 0 (0.0) 1 (0.8)
Lost to follow-up 23 (12.1) 5 (7.5) 18 (14.6)
Patient choice 11 (5.8) 3 (4.5) 8 (6.5)
Geographic reasons 3 (1.6) 1 (1.5) 2 (1.6)
Substance abuse 5 (2.6) 0 (0.0) 5 (4.1)
Non-compliance 4 (2.1) 0 (0.0) 4 (3.3)
Consent withdrawal 1 (0.5) 0 (0.0) 1 (0.8)
Other 1 (0.5) 1 (1.5) 0 (0.0)
Not available 105 (55.2) 42 (62.6) 63 (51.2)
ITT intention-to-treat; EVR early virologic response; EOT end-of-treatment; SVR sustained virologic response
a Data available for RediPEN only; n = 513
bDue to variable follow-up, if information at 24 weeks post-EOTwas unavailable for the evaluation of SVR24,
follow-up information ≥12 weeks post-EOTwas utilized for SVR assessment
c Proportion of discontinuation based on the total number of patients discontinued per population subgroup
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The results of the detailed SVR subgroup analysis are sum-
marized in Table 3. Overall, significant differences in SVR
achievement were observed between genotypes, with G3 being
associated with poorer response (74.4 % G2 vs. 63.6 % G3;
p<0.001). Fibrosis score (73.1 % F0/F1 vs. 52.6 % F2 vs.
66.0 % F3 vs. 41.9 % F4; p=0.003) and race (73.1 % Asian
vs. 59.1 % Caucasian vs. 20.0 % Black/Hispanic; p=0.010)
had a significant impact on SVR in the G3-infected population
only. No parameters in the G2-infected population were iden-
tified as predictors of SVR, although a statistical trend was
observed for the association between gender and SVR (male
vs. female: 72.3 % vs. 82.6 %; p=0.119). The effect of race on
SVR remained unchanged, even upon excluding the BOther^
race category.
Table 4 presents the results of the subgroup analysis for
relapse. Overall, a significant association was observed be-
tween relapse rate and genotype (G2 vs. G3: 12.7 % vs.
19.1 %; p=0.008). The association between fibrosis score
and relapse was significant in the G3-infected population
(8.1 % F0/F1 vs. 37.7 % F2 vs. 21.9 % F3/F4; p<0.001),
while gender was identified as a potential confounder
(26.4 % male vs. 18.0 % female; p=0.118). No associations
were found for race, weight, baseline HCV RNA levels, and
geographic location. Furthermore, no predictors of relapse
were identified for the G2-infected population.
Multivariate analysis
The results of the multivariate analysis are provided in Table 5.
Upon adjusting for potential confounders, genotype was iden-
tified as a significant predictor of response in terms of both
SVR and relapse: G3-infected patients had approximately







Genotype (G), n (%)a
2 468 (37.7) 468 (100)
3 774 (62.3) 774 (100)
Total 1242 (100.0)
Gender, male, n (%)b 318 (62.0) 101 (59.4) 217 (63.3)
Age, yearsb
Mean (SD) 45.4 (10.1) 49.6 (9.4) 43.4 (9.9)
Median 45.5 50.8 43.8
Range 18.4–76.8 21.1–76.8 18.4–70.6
Age categories, n (%)b
<25 16 (3.1) 3 (1.8) 13 (3.8)
25–39 122 (23.8) 19 (11.2) 103 (30.0)
40–54 300 (58.5) 109 (64.1) 191 (55.7)
≥55 75 (14.6) 39 (22.9) 36 (10.5)
Total 513 (100.0) 170 (100.0) 343 (100.0)
Race, n (%)b
Asian 35 (6.8) 9 (5.3) 26 (7.5)
Black/Hispanic 11 (2.1) 6 (3.5) 5 (1.5)
Caucasian 422 (82.3) 146 (85.9) 276 (80.5)
Other 45 (8.8) 9 (5.3) 36 (10.5)
Total 513 (100.0) 170 (100.0) 343 (100.0)
Weight category, kg, n (%)
40 to <50 29 (2.3) 18 (3.8) 11 (1.4)
50 to <64 198 (15.9) 68 (14.5) 130 (16.8)
64 to <75 272 (21.9) 86 (18.4) 186 (24.0)
75 to <85 298 (24.0) 107 (22.9) 191 (24.7)
≥85 444 (35.7) 189 (40.4) 255 (32.9)
Not available 1 (0.1) 0 (0.0) 1 (0.1)
Total 1242 (100.0) 468 (100.0) 774 (100.0)
Metavir fibrosis score, n (%)
F0/F1 150 (12.1) 72 (15.4) 78 (10.1)
F2 134 (10.8) 58 (12.4) 76 (9.8)
F3 89 (7.2) 36 (7.7) 53 (6.8)
F4 62 (5.0) 19 (4.1) 43 (5.6)
Not available 807 (65.0) 283 (60.5) 524 (67.7)
Total 1242 (100.0) 468 (100.0) 774 (100.0)
HCV RNA, log10 IU/mL
c
Mean (SD) 6.2 (6.5) 6.3 (6.6) 6.1 (6.4)
Median 5.9 5.9 5.8
Range 2.7–7.6 2.7–7.6 2.8–6.5
Length of treatment (weeks), n (%)
0 to <12 47 (3.8) 20 (4.3) 27 (3.5)
12–16 24 (1.9) 7 (1.5) 17 (2.2)
17 to <23 31 (2.5) 9 (1.9) 22 (2.8)
24 979 (78.8) 377 (80.6) 602 (77.8)
>24 to 47 64 (5.2) 26 (5.6) 38 (4.9)
48 15 (1.2) 2 (0.4) 13 (1.7)








Total 1242 (100) 468 (100.0) 774 (100.0)
Geographic region, n (%)
British Columbia 256 (20.6) 103 (22.0) 153 (19.8)
Atlantic Canadad 34 (2.7) 20 (4.3) 14 (1.8)
Ontario 581 (46.8) 229 (48.9) 352 (45.5)
Prairie provincese 188 (15.1) 77 (16.5) 111 (14.3)
Quebec 183 (14.7) 39 (8.3) 144 (18.6)
Total 1242 (100.0) 468 (100.0) 774 (100.0)
ITT intention-to-treat; SD standard deviation
a n= 1242
bData available for RediPEN only; n = 513
c n= 761
dAtlantic Canada includes New Brunswick, Newfoundland and Labra-
dor, and Nova Scotia
e Prairie provinces include Alberta, Manitoba, and Saskatchewan
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80 % lower odds of achieving SVR [odds ratio (OR) (95 %
confidence interval [CI]): 0.20 (0.06–0.64); p=0.007] and
nearly 7-fold higher odds of relapsing [OR (95 % CI): 6.84
(1.32–35.34); p = 0.022] when compared to G2-infected
individuals. Male gender [OR (95 % CI): 14.29 (1.25–
125.00); p=0.014] and more advanced fibrosis [F2 vs. F0/
F1: OR (95 % CI): 6.79 (1.42–35.52); p=0.017, F3/F4 vs.
F0/F1: OR (95 % CI): 2.38 (0.59–13.52); p=0.192] were also
Table 3 Subgroup analysis for SVR
Variable Overall ITT (n= 1242) Genotype 2 (n= 468) Genotype 3 (n= 774)
Yes, n (%) No, n (%) p-Value Yes, n (%) No, n (%) p-Value Yes, n (%) No, n (%) p-Value
Overall SVRa 840 (67.6) 402 (32.4) – 348 (74.4) 120 (25.6) – 492 (63.6) 282 (36.4) –
Genotype (G)
2 348 (74.4) 120 (25.6) <0.001* – – – – – –
3 492 (63.6) 282 (36.4)
Genderb
Male 203 (63.8) 115 (36.2) 0.082* 73 (72.3) 28 (27.7) 0.119* 130 (59.9) 87 (40.1) 0.342
Female 139 (71.3) 56 (28.7) 57 (82.6) 12 (17.4) 82 (65.1) 44 (34.9)
Raceb
Asian 27 (77.1) 8 (22.9) 0.137* 8 (88.9) 1 (11.1) 0.700 19 (73.1) 7 (26.9) 0.010*
Black/Hispanic 6 (54.5) 5 (45.5) 5 (83.3) 1 (16.7) 1 (20.0) 4 (80.0)
Caucasian 274 (64.9) 148 (35.1) 111 (76.0) 35 (24.0) 163 (59.1) 113 (40.9)
Other 35 (77.8) 10 (22.2) 6 (66.7) 3 (33.3) 29 (80.6) 7 (19.4)
Weight, kgb
40 to <50 22 (75.9) 7 (24.1) 0.869 13 (72.2) 5 (27.8) 0.916 9 (81.8) 2 (18.2) 0.536
50 to <64 134 (67.7) 64 (32.3) 49 (72.1) 19 (27.9) 85 (65.4) 45 (34.6)
64 to <75 180 (66.2) 92 (33.8) 63 (73.3) 23 (26.7) 117 (62.9) 69 (37.1)
75 to <85 204 (68.5) 94 (31.5) 78 (72.9) 29 (27.1) 126 (66.0) 65 (34.0)
≥85 300 (67.6) 144 (32.4) 145 (76.7) 44 (23.3) 155 (60.8) 100 (39.2)
Not availablec 0 (0.0) 1 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (100.0)
Metavir fibrosis scored
F0/F1 112 (74.7) 38 (25.3) 0.014* 55 (76.4) 17 (23.6) 0.844 57 (73.1) 21 (26.9) 0.003*
F2 83 (61.9) 51 (38.1) 43 (74.1) 15 (25.9) 40 (52.6) 36 (47.4)
F3 60 (67.4) 29 (32.6) 25 (69.4) 11 (30.6) 35 (66.0) 18 (34.0)
F4 33 (53.2) 29 (46.8) 15 (78.9) 4 (21.1) 18 (41.9) 25 (58.1)
Not availablec 552 (68.4) 255 (31.6) 210 (74.2) 73 (25.8) 342 (65.3) 182 (34.7)
HCV RNA baseline (log10 IU/mL)
Low: ≤5 75 (72.8) 28 (27.2) 0.178 29 (82.9) 6 (17.1) 0.336 46 (67.6) 22 (32.4) 0.238
High: >5 435 (66.1) 223 (33.9) 194 (75.5) 63 (24.5) 241 (60.1) 160 (39.9)
Not availablec 330 (67.6) 151 (32.4) 125 (71.0) 51 (29.0) 205 (67.2) 100 (32.8)
Geographic location
British Columbia 183 (71.5) 73 (28.5) 0.645 77 (74.8) 26 (25.2) 0.473 106 (69.3) 47 (30.7) 0.277
Atlantic Canadae 23(67.6) 11 (32.4) 15 (75.0) 5 (25.0) 8 (57.1) 6 (42.9)
Ontario 388 (66.8) 193 (33.2) 174 (76.0) 55 (24.0) 214 (60.8) 138 (39.2)
Prairie provincesf 127 (67.6) 61 (32.4) 51 (66.2) 26 (33.8) 76 (68.5) 35 (31.5)
Quebec 119 (65.0) 64 (35.0) 31 (79.5) 8 (20.5) 88 (61.1) 56 (38.9)
ITT intention-to-treat; SVR sustained virologic response
*Variables included in the multivariate analysis (p< 0.150)
a% based on the total number of patients with available data for each level of each variable
b Data available for RediPEN only; n = 513
cNot available categories excluded from statistical comparison
d For the total number of patients with available SVR data per fibrosis level, refer to Fig. 1c
e Atlantic Canada includes New Brunswick, Newfoundland and Labrador, and Nova Scotia
f Prairie provinces include Alberta, Manitoba, and Saskatchewan
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identified as independent predictors of relapse in the overall
ITT population. Race was not found to have an effect on
SVR, irrespective of including or not the BOther^ race
category.
With regards to the individual genotypes, given that no
significant predictors were identified for G2-infected patients
in the univariate analyses (Tables 3 and 4), multivariate
analyses were not conducted. However, within the
Table 4 Subgroup analysis for relapse
Variable Overall ITT (n = 982) Genotype 2 (n = 386) Genotype 3 (n = 596)
Yes, n (%) No, n (%) p-Value Yes, n (%) No, n (%) p-Value Yes, n (%) No, n (%) p-Value
Overall relapse ratea 163 (16.6) 819 (83.4) – 49 (12.7) 337 (87.3) – 114 (19.1) 482 (80.9) –
Genotype (G)
2 49 (12.7) 337 (87.3) 0.008* – – – – – –
3 114 (19.1) 482 (80.9)
Genderb
Male 49 (20.4) 191 (79.6) 0.137* 6 (7.8) 71 (92.2) 0.983 43 (26.4) 120 (73.6) 0.118*
Female 22 (14.5) 130 (85.5) 4 (7.7) 48 (92.3) 18 (18.0) 82 (82.0)
Raceb
Asian 4 (13.3) 26 (86.7) 0.827 0 (0.0) 8 (100.0) 0.225 4 (18.2) 18 (81.8) 0.308
Black/Hispanic 1 (16.7) 5 (83.3) 0 (0.0) 4 (100.0) 1 (50.0) 1 (50.0)
Caucasian 60 (19.0) 256 (81.0) 8 (7.3) 101 (92.7) 52 (25.1) 155 (74.9)
Other 6 (15.0) 34 (85.0) 2 (25.0) 6 (75.00) 4 (12.5) 28 (87.5)
Weight, kgb
40 to <50 3 (12.5) 21 (87.5) 0.917 3 (20.0) 12 (80.0) 0.490 0 (0.0) 9 (100.0) 0.623
50 to <64 28 (17.4) 133 (82.6) 10 (17.2) 48 (82.8) 18 (17.5) 85 (82.5)
64 to <75 39 (18.2) 175 (81.8) 11 (15.3) 61 (84.7) 28 (19.7) 114 (80.3)
75 to <85 38 (16.0) 199 (84.0) 9 (10.7) 75 (89.3) 29 (19.0) 124 (81.0)
≥85 55 (15.9) 291 (84.1) 16 (10.2) 141 (89.8) 39 (20.6) 150 (79.4)
Not availablec 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.1)
Metavir fibrosis scored,e
F0/F1 15 (12.1) 109 (87.9) 0.006* 10 (16.1) 52 (83.9) 0.633 5 (8.1) 57 (91.9) <0.001*
F2 31 (28.2) 79 (71.8) 8 (16.3) 41 (83.7) 23 (37.7) 38 (62.3)
F3/F4 18 (17.3) 86 (82.7) 4 (10.0) 36 (90.0) 14 (21.9) 50 (78.1)
Not availablec 99 (15.4) 545 (84.6) 27 (11.4) 208 (88.6) 72 (17.6) 337 (82.4)
HCV RNA baseline (log10 IU/mL)
Low: ≤5 13 (14.9) 74 (85.1) 0.651 2 (6.7) 28 (93.3) 0.334 11 (19.3) 46 (80.7) 0.922
High: >5 85 (16.9) 418 (83.1) 27 (12.8) 184 (87.2) 58 (19.9) 234 (80.1
Not availablec 65 (16.6) 327 (83.4) 20 (13.8) 125 (86.2) 45 (18.2) 202 (79.2)
Geographic location
British Columbia 34 (15.8) 181 (84.2) 0.945 13 (14.6) 76 (85.4) 0.290 21 (16.7) 105 (83.3) 0.945
Atlantic Canadaf 5 (17.9) 23 (82.1) 3 (16.7) 15 (83.3) 2 (20.0) 8 (80.0)
Ontario 71 (16.0) 372 (84.0) 19 (10.3) 165 (89.7) 52 (20.1) 207 (79.9)
Prairie provincesg 29 (17.8) 126 (81.3) 12 (19.0) 51 (81.0) 17 (18.5) 75 (81.5)
Quebec 24 (17.0) 117 (83.0) 2 (6.3) 30 (93.8) 22 (20.0) 87 (79.8)
ITT intention-to-treat
*Variables included in the multivariate analysis (p< 0.150)
a% based on the total number of patients with available data for each level for each variable
b Data available for RediPEN only; n = 513
cNot available categories excluded from statistical comparison
dDue to the low numbers, F3 and F4 were combined in the univariate and multivariate analyses of relapse
e For the total number of patients with available relapse data per fibrosis level, refer to Fig. 1d
f Atlantic Canada includes New Brunswick, Newfoundland and Labrador, and Nova Scotia
g Prairie provinces include Alberta, Manitoba, and Saskatchewan
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Fig. 1 Treatment outcome by
genotype per fibrosis score.
Proportion of patients by hepatitis
C virus (HCV) genotype and
baseline Metavir fibrosis score
for the following treatment
outcomes: early virologic
response (EVR) (panel A;
collected for RediPEN only:
G2 n= 170; G3 n= 343);
end-of-treatment (EOT) response
(panel B: G2 n = 468, G3
n= 774); sustained virologic
response (SVR) (panel C: G2
n= 468, G3 n= 774); relapse
(panel D; calculated for patients
achieving an EOT response:
G2 n= 386; G3 n= 596). The
BTotal^ category includes all
patients with available fibrosis
data. Per genotype, the p-value
for the association between
fibrosis stage and treatment
outcome is provided. Patients
lost to follow-up or with
missing EVR, EOT response,
and SVR information were
considered as non-responders
604 Eur J Clin Microbiol Infect Dis (2016) 35:597–609
G3-infected population, fibrosis score was identified as a
significant predictor of both SVR and relapse: F2 patients
had 60 % lower odds of achieving SVR compared to F0/F1
patients [OR (95 % CI): 0.41 (0.21–0.80); p=0.009], F3
patients had 30 % lower odds [OR (95 % CI): 0.72 (0.34–
1.53); p=0.388], and F4 patients had over 70 % lower odds
[OR (95 % CI): 0.27 (0.12–0.58); p=0.001]. Although, in
the univariate analysis, race was found to be significantly
associated with SVR, due to instability of the model caused
by the low number of patients with available information, it
was excluded from the multivariate analysis. Regarding
relapse, when compared to F0/F1 individuals, F2 patients
had nearly 10-fold higher odds [OR (95 % CI): 9.72
(1.52–61.99); p=0.016] and F3/F4 patients had 4-fold higher
odds of relapsing [OR (95 % CI): 4.23 (0.71–25.24);
p=0.113]. Relapse was also significantly associated with gen-
der, with male patients having 13-fold higher odds of relaps-
ing than females [OR (95 % CI): 13.16 (1.49–111.11);
p=0.020]. No significant independent predictors of EVR or
EOTwere identified.
Safety
As observational studies, neither RediPEN nor PoWer
were mandated, at the time of study conduct, to collect
information on safety. In addition, reasons for discontin-
uation were recorded only in the RediPEN study
(Table 1). Overall, 190 patients discontinued treatment,
with adverse events (n= 35) being the primary cause in
34 patients [6.6 % of the RediPEN population: 8.8 %
(n = 15) of G2-infected RediPEN patients and 5.5 %
(n= 19) of G3-infected RediPEN patients] (Table 1) .
Discussion
The safety and efficacy of peg-IFN α-2b plus ribavirin for the
treatment of chronic HCV infection has been previously eval-
uated in several controlled clinical trials [7, 11–13, 16, 17,
30–36]. The purpose of this pooled analysis was to separately
evaluate, in a large Canadian cohort, the real-world effective-
ness of PEGETRON® for the treatment of chronic HCV in-
fection in treatment-naïve individuals with G2 and G3 HCV
infection. Observational studies are essential in order to dem-
onstrate the true population-based benefits. In addition, pre-
dictors of treatment response were evaluated.
Per genotype, G3 was associated with lower odds of
achieving SVR and higher odds of relapse compared to G2.
These results are in line with previous reports that have found
differences in therapeutic outcomes between G2- and G3-
infected populations, where G3 infection has been associated
with attenuated treatment responses and higher rates of relapse
compared to G2 infection [7, 11–14, 33, 37]. Furthermore,
among G3-infected patients, a significant association was ob-
served between advanced liver disease (indicated by more
severe fibrosis) and response to treatment. These findings
are consistent with previous reports indicating that advanced
liver disease is a predictor of higher treatment failure and
lower SVR rates [7, 33, 37], especially in G3-infected pa-
tients: Powis et al. demonstrated that cirrhotic G3-infected
patients experience lower SVR rates (17 % vs. 78 %;
p=0.027) [7, 37] than their cirrhotic G2-infected counterparts,
and Aghemo et al. reported higher rates of treatment failure in
cirrhotic versus non-cirrhotic G3-infected individuals [OR (95
% CI): 10.1 (2.4–41.7)] [37].
Interestingly, significant associations between gender and
relapse were observed in both the ITT and G3-infected
Table 5 Multivariate logistic
regression analysisa Population Outcome Variable Level Odds ratio (95 % CI) p-Value
ITT SVR Genotype Genotype 3 vs. 2 0.20 (0.06–0.64) 0.007
Relapseb Genotype Genotype 3 vs. 2 6.84 (1.32–35.34) 0.022
Gender Male vs. female 14.29 (1.70–125.00) 0.014
Fibrosis score F2 vs. F0/F1 6.79 (1.42–32.52) 0.017
F3/F4 vs. F0/F1 2.38 (0.59–13.52) 0.192
Genotype 3 SVRc Fibrosis score F2 vs. F0/F1 0.41 (0.21–0.80) 0.009
F3 vs. F0/F1 0.72 (0.34–1.53) 0.388
F4 vs. F0/F1 0.27 (0.12–0.58) 0.001
Relapseb Gender Male vs. female 13.16 (1.49–111.11) 0.020
Fibrosis score F2 vs. F0/F1 9.72 (1.52–61.99) 0.016
F3/F4 vs. F0/F1 4.23 (0.71–25.24) 0.113
CI confidence interval; ITT intention-to-treat; SVR sustained virologic response
a Significant variables from saturated multivariate models (p < 0.05). Multivariate analysis was not conducted for
G2 since only gender was identified as a potential predictor in the univariate analysis
b Due to the low numbers, F3 and F4 were combined in the relapse analysis
c Race was excluded from the model due to numerical instability (low numbers)
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populations. Although numerous reports have identified female
gender as an independent predictor of spontaneous viral clear-
ance [38–42], limited evidence is available for the association
between gender and treatment outcomes: while Manns et al.
have previously identified an association between gender and
SVR [33], numerous publications have failed to identify gender
as an independent predictor of response to peg-IFNα+RBV
combination therapy [7, 11–13]. However, in individuals with
chronic HCV infection, more rapid rates of fibrosis progression
have been found in men [43–46], with evidence supporting
beneficial effects of estrogen slowing the progression of liver
fibrosis in women [47, 48]. In addition, Hayashi et al. found
that, although there was no significant gender difference in the
overall response to IFN-αmonotherapy, being a younger wom-
an (<40 years) was a favorable marker for successful treatment
[49], findings substantiated by subsequent data associating
menopause with a significant decrease in treatment response
and acceleration of liver fibrosis, when compared to women
of reproductive age and, thus, higher estrogen levels [45, 47].
In accordance with the observation nature of the RediPEN
and PoWer studies, this pooled analysis was limited primarily
by the incomplete baseline data regarding race, fibrosis score,
gender, andweight, which were only available for the RediPEN
study. Viral load data were also incomplete, with 40 % or more
of patientsmissing this information at baseline. Previous studies
have identified race as a significant risk factor for poor response
to treatment due to a higher prevalence of favorable allelic
variations at the IL28B promoter in certain ethnic populations
[14, 32, 34, 50], and baseline viral load has previously been
identified as a predictor of treatment response [7, 11, 13, 14,
30]. Also, a major limitation of the study was the lack of RVR
data collected. RVR has been shown to predict treatment re-
sponse in G2 and G3 patients treated with peg-IFNα+RBV
combination therapy, where, in those patients achieving RVR,
shorter treatment regimens (12–16 weeks) have been found to
be as effective as the standard 24-week treatment [11, 30, 34,
36]. However, as best practice to shorten HCV therapy based
on prognostic indicators, including RVR, was not dictated by
Canadian HCV treatment guidelines until 2007, the lack of
RVR data collected is an accurate reflection of the treatment
algorithms advocated at the time of the conduct of both studies
[51]. This is corroborated by the less than 2 % of patients
overall who received an abbreviated 12–16-week treatment reg-
imen, with the majority of patients receiving the full 24 weeks
recommended (78.8 % in the ITT population).
An additional limitation of the current analysis is the
lack of steatosis data. Especially important in patients
with G3 [8–10], steatosis has been associated with
higher rates of relapse in this patient subgroup [52,
53]. As such, we were unable to assess the contribution
of steatosis to treatment outcomes, or lack thereof, in
G3 patients. Also, assessment of the IL28 genetic poly-
morphism, a known predictor of treatment response, was
not part of the two studies analyzed. However at the
time of the conduct of the studies, the genetic contribu-
tion to anti-HCV treatment response, specifically IL28
[54, 55], was not characterized, and, thus, genotyping
patients was not standard of care [51]. Furthermore,
due to the fact that, at the time of study conduct, the
collection of adverse events during observational re-
search was not mandated by regulatory agencies, all
adverse events documented pertain to treatment discon-
tinuation alone, the extent of missing information does
not permit a comprehensive safety analysis.
In addition, we report a strikingly lower proportion of pa-
tients experiencing EVR than the approximately 90 % EVR
rates reported for G2/G3 patients in the literature [30, 56, 57].
However, due to the ITT approach taken by the current
analysis, all patients lost to follow-up, or with missing EVR,
EOT response, and SVR information, were considered as non-
responders. As such, EVR, which was collected for RediPEN
only, was available for 23.2 % of patients (n =119). However,
when calculated based on the number of patients with
available data, EVR occurred in 89.9 % of patients overall,
and in 94.7 % of G2 and 87.7 % of G3 patients. These values
are comparable to those reported in the literature, where a
study by Shiffman et al. found EVR rates of 89 % overall
(G2 and G3 combined), and in 94 % of G2 and 85 % of G3
patients, treated with PEG/RBV for 24 weeks, respectively
[30]. Although this may be an over-estimation of EVR, the
high proportion of patients with missing data may be used to
rationalize a less conservative approach in the discussion of
this outcome.
Nonetheless, the external validity of our findings is not com-
promised, as we provide evidence from a large cohort
supporting, in a real-world setting, the effectiveness of peg-
IFN α-2b plus ribavirin in the treatment of chronic HCV G2
and G3 infections. In addition, our data not only substantiate
recent evidence identifying G3 as a poor prognostic marker
when compared to G2, but also confirm fibrosis and indicate
gender as important predictors of treatment outcome in G3-
infected patients.
Up until recently, treatment guidelines were unanimous in
their recommendations of dual combination therapy for the
treatment of HCV G2–6 infections, and triple combination
therapy for G1 infection. However, the 2014 recommenda-
tions put forth by the American Association for the Study of
Liver Diseases (AASLD), as well as the most recent guide-
lines from the Canadian Association for the Study of the Liver
(CASL) recommend first-line SOF dual combination therapy
with ribavirin for the treatment of G2 and G3 [24, 25]. Al-
though SVR rates achieved are promising [21–23], the advan-
tage of SOF over PEG/RBV is restricted by its cost, as the
price tag on a 12-week course of therapy is CAD $55,000 and
USD $84,000, both of which exclude the price of ribavirin
[58]. Furthermore, both the AASLD and CASL guidelines
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recommended a 12-week course of treatment for G2 infec-
tions, and 24 weeks for G3 infections, doubling the projected
costs for G3-infected patients [24, 25].
The outcomes of several recent cost-effectiveness analyses
have found that SOF regimens at their current costs, specifi-
cally with regards to the treatment of treatment-naïve, non-
cirrhotic G2 and G3 patients, are less cost-effective than
PEG/RBV when considering ICERs in the context of WTP
thresholds of up to $100,000 [26–29]. Furthermore, in order to
achieve cost-effectiveness in G2 and G3 patients, Najafzadeh
et al. report that the cost of SOF-containing regimens would
have to cost less than $4500 and $5500 dollars a week, re-
spectively [28]. Based on the results of the current analysis
and taking into consideration the proven clinical and
cost effectiveness of peg-IFN α plus ribavirin for the
treatment of HCV [59], treatment with PEG/RBV re-
mains an effective and viable alternative in subsets of
G2 and G3 HCV-infected patients, particularly in treat-
ment-naïve individuals with lower fibrosis scores, and
reimbursement limitations.
Acknowledgments The authors would like to thank all the participat-
ing investigators in the PoWer and RediPEN studies:
Abu Hamour, Alnoor Ramji, Andrew Bellini, Andrew Chan, Anthony
Hammer, Arshad Khalil, Asad Khan, B. Borthistle, Barbara Desir,
Barbara Romanowski, Bashirubin Sachedina, Bernard Lessard, Bernard
Rousseau, Brent Derksen, Brian Chai, Brian Conway, Cameron Ghent,
Catherine Lowe, Celina Beaulieu, Chris Fraser, Chris Stabler, Chris
Steingart, Christopher Stabler, Chrystian Dallaire, Claire Beliveau,
Claude Bernier, Claude Briere, Craig Kuhn, Craig Lee, Dalia El-Ashry,
Daniel Menard, Danny Chen, David A. Miller, David Kreaden, David
Miller, David Pearson, David Wong, Davinder Tripathi, Denis Levesque,
Dennis Kunimoto, Donald Kilby, Doria Grimard, Doug Hemphill, Doug-
las Hemphill, Douglas Simmonds, Dwight Ferris, Earle Morgan, Earle P.
Morgan, Edward Lin, Elisa Venier, Eric Hurowitz, Eric Leong, Eric
Partlow, Fiona Duncan, Florence Wong, Francis Dicum, Francisco
Diaz-Mitoma, Frank H. Anderson, Frank Schwiger, Gabor Kandel,
Geoffrey Taylor, Gerald Chan, Gilles Faust, Gilles Pinette, Glen Fallows,
Gordon S. Bierbrier, Craig Joseph Kuhn, Hanna E. Binder, Helena Lau,
Helga Witt-Sullivan, Henry Wong, Henryk Pluta, Hsiao-Ming Jung,
Imran Rasul, Isabelle Chiu, Issam El-Takli, Jacinthe Larouche, Jack
Amar, James D. Mchattie, Jean-Francois Paradis, Jean-Rene Lachance,
Jean Robert, Jeff Daiter, Jeffrey L. Axler, Joanne Hamel, Joe Anderson,
Johann de la Rey Nel, John Farley, Jonathon Springer, Jordan Golubov,
K. Menon, Karen Doucette, Keith Bovell, Keith Phillips, Keith Wong,
Kelly W. Burak, Ken Lee, Kenneth Atkinson, Kevin Lai, Kevorak
Peltekian, Kim Tilbe, Kiran Madala, Krishna Menon, Lawrence A. Ed-
wards, Lawrence Fredeen, Lawrence Halperin, Lawrence B. Lilly, Linda
Scully, Lorne Tyrell, Lucie Deshaies, Lynora Saxinger, Magdy Elkashab,
MangMa, Marc Bradette, Marc Poliquin, Marcia Prest, Marc Joffe, Mark
Levsitk, Marty Fishman, Michael Lingley, Michael Oravec, Michael
Varenbut, Micheal Gould, Michel Booth, Miller Macsween, N. Anand,
Naoki Chiba, Nathan Frank, Navid Anand, Neal Belluzzo, Nir Hilzenrat,
Oscar Koller, Osman Tarabain, Paige Emenau, Peter J. Campbell, Pierre
Coté, Pierre Hallé, Pierre Laberge, Pierre Paré, Pina Michieletti, R.
Pennier, Rahman Bacchus, Raymond Bourdages, Rejean Dubé, Richard
Housley, Rima Petroniene, Rob Baker, Robert Bailey, Robert Clark,
Robert Enns, Robert P. Myers, Roger Mousseau, Sam A. Friedlander,
Satchan Takaya, Saya Victor Feinman, Scott Fung, Sidney Sabbah, Ste-
phen G. Holland, Stephen Shafran, Supriya Joshi, Susun Greenbloom,
Sylvain Lavoie, Sylvester Ukabam, Taralyn Picton, Terry Maguire,
Theodore Ptak, Tim Devlin, Vinod Puri, Vinod Sharma, Wayne
Ghesquire, William Appell, William Depew, William Lewis, Yolande
Westra, Yoon-Jae Lee.
Compliance with ethical standards
Funding This study was funded by Merck Canada Inc.
Conflict of interest Dr. Paul Marotta has received payment for the
development of education presentations; Dr. Robert Bailey has received
honorarium for professional services; Dr. Magdy Elkashab has been com-
pensated for past consultancy, and is the recipient of grants for research
currently ongoing; Dr. John Farley has been compensated for advisory
board consultancy, has received honoraria for lectures, as well as travel
and accommodation compensation for international conference participa-
tion; Dr. Kevorak Peltekian has served as a board member for Merck, and
has received personal compensation for travel related to study activities,
also from Merck; Dr. Marc Poliquin has received compensation for con-
ference participation fromMerck, Gilead, AbbVie, Shire, and Roche, and
has received consulting fees for Merck, Gilead, AbbVie, and Vertex; Dr.
Witt-Sullivan has received fees for consultancy; Martine Drolet is an
employee ofMerck Canada Inc., and has received financial compensation
for manuscript preparation, is a shareholder with Merck Canada Inc., and
has been reimbursed for travel and accommodations expenses by Merck
Canada Inc.; Dr. Emmanouil Rampakakis is an employee of JSS Medical
Research Inc., and has received compensation fromMerck for manuscript
development and statistical analysis; Dr. Curtis Cooper has received com-
pensation for advisory board participation, payment for lectures related to
HCV, and travel and accommodation compensation related to conference
participation; Dr. Feinman declares no conflicts of interest.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. World Health Organization (WHO) (2010) Resolutions from the
Sixty-third World Health Assembly (WHA63). WHO
2. Lavanchy D (2011) Evolving epidemiology of hepatitis C virus.
Clin Microbiol Infect 17(2):107–115
3. Myers RP, KrajdenM, BilodeauM,Kaita K,Marotta P, Peltekian K
et al (2014) Burden of disease and cost of chronic hepatitis C in-
fection in Canada. Can J Gastroenterol Hepatol 28(5):243–250
4. Zou S, Tepper M, El Saadany S (2000) Prediction of hepatitis C
burden in Canada. Can J Gastroenterol 14(7):575–580
5. Public Health Agency of Canada (PHAC) (2009) Epidemiology of
acute hepatitis C infection in Canada: results from the Enhanced
Hepatitis Strain Surveillance System (EHSSS)
6. Amarapurkar D (2000) Natural history of hepatitis C virus infec-
tion. J Gastroenterol Hepatol 15(Suppl):E105–E110
7. Powis J, Peltekian KM, Lee SS, ShermanM, Bain VG, Cooper C et
al (2008) Exploring differences in response to treatment with
peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C
between genotypes 2 and 3. J Viral Hepat 15(1):52–57
8. Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z,
Zeuzem S et al (2003) Effect of treatment with peginterferon or
Eur J Clin Microbiol Infect Dis (2016) 35:597–609 607
interferon alfa-2b and ribavirin on steatosis in patients infected with
hepatitis C. Hepatology 38(1):75–85
9. Mihm S, Fayyazi A, Hartmann H, Ramadori G (1997) Analysis of
histopathological manifestations of chronic hepatitis C virus infec-
tion with respect to virus genotype. Hepatology 25(3):735–739
10. Asselah T, Rubbia-Brandt L, Marcellin P, Negro F (2006) Steatosis
in chronic hepatitis C: why does it really matter? Gut 55(1):123–
130
11. von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J,
Heintges T et al (2005) Peginterferon-alpha-2a (40KD) and ribavi-
rin for 16 or 24 weeks in patients with genotype 2 or 3 chronic
hepatitis C. Gastroenterology 129(2):522–527
12. Brown RS Jr, Jacobson IM, Afdhal N, Freilich B, Pauley BP,
Regenstein F, Flamm S, Kwo P, Griffel L, Brass CA, and the
WIN-R Study Group (2006) Differences in treatment outcome to
antiviral therapy based on genotype and viral load in hepatitis c
genotypes 2 and 3 in the WIN-R Trial. Abstract 41, EASL
13. Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P,
Sanchez-Tapias J et al (2004) Peginterferon alfa-2b plus ribavirin
for treatment of chronic hepatitis C in previously untreated patients
infected with HCV genotypes 2 or 3. J Hepatol 40(6):993–999
14. Andriulli A, Mangia A, Iacobellis A, Ippolito A, Leandro G,
Zeuzem S (2008) Meta-analysis: the outcome of anti-viral therapy
in HCV genotype 2 and genotype 3 infected patients with chronic
hepatitis. Aliment Pharmacol Ther 28(4):397–404
15. Lange CM, Jacobson IM, Rice CM, Zeuzem S (2014) Emerging
therapies for the treatment of hepatitis C. EMBOMol Med 6(1):4–
15
16. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M,
Marcellin P et al (2004) Peginterferon-alpha2a and ribavirin com-
bination therapy in chronic hepatitis C: a randomized study of treat-
ment duration and ribavirin dose. Ann Intern Med 140(5):346–355
17. MannsMP,McHutchison JG, Gordon SC, Rustgi VK, ShiffmanM,
Reindollar R et al (2001) Peginterferon alfa-2b plus ribavirin com-
pared with interferon alfa-2b plus ribavirin for initial treatment of
chronic hepatitis C: a randomised trial. Lancet 358(9286):958–965
18. Myers RP, Ramji A, Bilodeau M, Wong S, Feld JJ (2012) An
update on the management of hepatitis C: consensus guidelines
from the Canadian Association for the study of the liver. Can J
Gastroenterol 26(6):359–375
19. Yee HS, Chang MF, Pocha C, Lim J, Ross D, Morgan TR et al
(2012) Update on the management and treatment of hepatitis C
virus infection: recommendations from the Department of
Veterans Affairs Hepatitis C Resource Center Program and the
National Hepatitis C Program Office. Am J Gastroenterol 107(5):
669–689; quiz 690
20. Pawlotsky J (2014) EASL Clinical Practice Guidelines: manage-
ment of hepatitis C virus infection. J Hepatol 60(2):392–420
21. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T,
Gordon SC et al (2013) Sofosbuvir for previously untreated chronic
hepatitis C infection. N Engl J Med 368(20):1878–1887
22. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-
Torres M, Sulkowski MS et al (2013) Sofosbuvir for hepatitis C
genotype 2 or 3 in patients without treatment options. N Engl JMed
368(20):1867–1877
23. Zeuzem S,Dusheiko GM, Salupere R,Mangia A, Flisiak R,Hyland
RH, Illeperuma A, Svarovskaia ES, Brainard DM, Symonds WT,
Hutchinson JG, Weiland O, Reesink HW, Ferenci P, Hézode C,
Esteban R (2013) Sofosbuvir + ribavirin for 12 or 24 weeks for
patients with HCV genotype 2 or 3: the VALENCE trial. Abstract
10-15-2013b;733A. Presented at the 64th Annual Meeting of the
American Association for the Study of Liver Diseases: The Liver
Meeting 2013, Washington, DC, November 2013
24. American Association for the Study of Liver Diseases (AASLD)
(2014) Recommendations for testing, managing, and treating hep-
atitis C
25. Myers RP, Shah H, Burak KW, Cooper C, Feld JJ (2015) An update
on the management of chronic hepatitis C: 2015 Consensus guide-
lines from the Canadian Association for the Study of the Liver. Can
J Gastroenterol Hepatol 29(1):19–34
26. Chhatwal J, Kanwal F, Roberts MS, Dunn MA (2015) Cost-
effectiveness and budget impact of hepatitis C virus treatment with
sofosbuvir and ledipasvir in the United States. Ann Intern Med
162(6):397–406
27. Linas BP, Barter DM, Morgan JR, Pho MT, Leff JA, Schackman
BR et al (2015) The cost-effectiveness of sofosbuvir-based regi-
mens for treatment of hepatitis C virus genotype 2 or 3 infection.
Ann Intern Med 162(9):619–629
28. Najafzadeh M, Andersson K, Shrank WH, Krumme AA, Matlin
OS, Brennan T et al (2015) Cost-effectiveness of novel regimens
for the treatment of hepatitis C virus. Ann Intern Med 162(6):407–
419
29. San Miguel R, Gimeno-Ballester V, Blázquez A, Mar J (2015)
Cost-effectiveness analysis of sofosbuvir-based regimens for chron-
ic hepatitis C. Gut 64(8):1277–1288
30. ShiffmanML, Suter F, Bacon BR, Nelson D, Harley H, Solá R et al
(2007) Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in
HCV genotype 2 or 3. N Engl J Med 357(2):124–134
31. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G et
al (1998) Randomised trial of interferon alpha2b plus ribavirin for
48weeks or for 24weeks versus interferon alpha2b plus placebo for
48 weeks for treatment of chronic infection with hepatitis C virus.
International Hepatitis Interventional Therapy Group (IHIT).
Lancet 352(9138):1426–1432
32. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM,
Rustgi VK et al (1998) Interferon alfa-2b alone or in combination
with ribavirin as initial treatment for chronic hepatitis C. Hepatitis
Interventional Therapy Group. N Engl J Med 339(21):1485–1492
33. MannsM, Zeuzem S, SoodA, Lurie Y, CornbergM, Klinker H et al
(2011) Reduced dose and duration of peginterferon alfa-2b and
weight-based ribavirin in patients with genotype 2 and 3 chronic
hepatitis C. J Hepatol 55(3):554–563
34. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M
et al (2005) Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks
in HCV genotype 2 or 3. N Engl J Med 352(25):2609–2617
35. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G,
Gonçales FL Jr et al (2002) Peginterferon alfa-2a plus ribavirin
for chronic hepatitis C virus infection. N Engl J Med 347(13):
975–982
36. Lagging M, Langeland N, Pedersen C, Färkkilä M, Buhl MR,
Mørch K et al (2008) Randomized comparison of 12 or 24 weeks
of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus
genotype 2/3 infection. Hepatology 47(6):1837–1845
37. Aghemo A, Rumi MG, Soffredini R, D’Ambrosio R, Ronchi G,
Del Ninno E et al (2006) Impaired response to interferon-alpha2b
plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus
infection. Antivir Ther 11(6):797–802
38. Bakr I, Rekacewicz C, El Hosseiny M, Ismail S, El Daly M, El-
Kafrawy S et al (2006) Higher clearance of hepatitis C virus infec-
tion in females compared with males. Gut 55(8):1183–1187
39. Grebely J, Page K, Sacks-Davis R, van der Loeff MS, Rice TM,
Bruneau J et al (2014) The effects of female sex, viral genotype, and
IL28B genotype on spontaneous clearance of acute hepatitis C virus
infection. Hepatology 59(1):109–120
40. Kenny-Walsh E (1999) Clinical outcomes after hepatitis C infection
from contaminated anti-D immune globulin. Irish Hepatology
Research Group. N Engl J Med 340(16):1228–1233
41. Wang CC, Krantz E, Klarquist J, Krows M, McBride L, Scott EP et
al (2007) Acute hepatitis C in a contemporary US cohort: modes of
acquisition and factors influencing viral clearance. J Infect Dis
196(10):1474–1482
608 Eur J Clin Microbiol Infect Dis (2016) 35:597–609
42. WieseM, Grüngreiff K, GüthoffW, LafrenzM, Oesen U, Porst H et
al (2005) Outcome in a hepatitis C (genotype 1b) single source
outbreak in Germany—a 25-year multicenter study. J Hepatol
43(4):590–598
43. Deuffic-Burban S, Poynard T, Valleron AJ (2002) Quantification of
fibrosis progression in patients with chronic hepatitis C using a
Markov model. J Viral Hepat 9(2):114–122
44. Poynard T, Bedossa P, Opolon P (1997) Natural history of liver
fibrosis progression in patients with chronic hepatitis C. The
OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.
Lancet 349(9055):825–832
45. Villa E, Karampatou A, Cammà C, Di Leo A, Luongo M, Ferrari A
et al (2011) Early menopause is associated with lack of response to
antiviral therapy in women with chronic hepatitis C.
Gastroenterology 140(3):818–829
46. Wright M, Goldin R, Fabre A, Lloyd J, Thomas H, Trepo C et al
(2003)Measurement and determinants of the natural history of liver
fibrosis in hepatitis C virus infection: a cross sectional and longitu-
dinal study. Gut 52(4):574–579
47. Di Martino V, Lebray P, Myers RP, Pannier E, Paradis V, Charlotte
F et al (2004) Progression of liver fibrosis in women infected with
hepatitis C: long-term benefit of estrogen exposure. Hepatology
40(6):1426–1433
48. Villa E, Vukotic R, Cammà C, Petta S, Di Leo A, Gitto S et al
(2012) Reproductive status is associatedwith the severity of fibrosis
in women with hepatitis C. PLoS One 7(9):e44624
49. Hayashi J, Kishihara Y, Ueno K, Yamaji K, Kawakami Y, Furusyo
N et al (1998) Age-related response to interferon alfa treatment in
women vs men with chronic hepatitis C virus infection. Arch Intern
Med 158(2):177–181
50. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM,
Reddy KR, Bzowej NH et al (2011) Telaprevir for previously un-
treated chronic hepatitis C virus infection. N Engl J Med 364(25):
2405–2416
51. Sherman M, Shafran S, Burak K, Doucette K, Wong W, Girgrah N
et al (2007) Management of chronic hepatitis C: consensus guide-
lines. Can J Gastroenterol 21(Suppl C):25C–34C
52. Restivo L, Zampino R, Guerrera B, Ruggiero L, Adinolfi LE
(2012) Steatosis is the predictor of relapse in HCV genotype
3- but not 2-infected patients treated with 12 weeks of
pegylated interferon-alpha-2a plus ribavirin and RVR. J
Viral Hepat 19(5):346–352
53. Shah SR, Patel K, Marcellin P, Foster GR, MannsM, Kottilil S et al
(2011) Steatosis is an independent predictor of relapse following
rapid virologic response in patients with HCV genotype 3. Clin
Gastroenterol Hepatol 9(8):688–693
54. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ et
al (2009) Genetic variation in IL28B predicts hepatitis C treatment-
induced viral clearance. Nature 461(7262):399–401
55. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K,
Sakamoto N et al (2009) Genome-wide association of IL28B with
response to pegylated interferon-alpha and ribavirin therapy for
chronic hepatitis C. Nat Genet 41(10):1105–1109
56. Berg T, Carosi G (2008) Optimizing outcomes in patients with
hepatitis C virus genotype 2 or 3. Antivir Ther 13(Suppl 1):17–22
57. Yu JW,Wang GQ, Sun LJ, Li XG, Li SC (2007) Predictive value of
rapid virological response and early virological response on
sustained virological response in HCV patients treated with
pegylated interferon alpha-2a and ribavirin. J Gastroenterol
Hepatol 22(6):832–836
58. Hepatitis C Education and Prevention Society (HEPCBC) (2015)
Updates to Canadian sofosbuvir pricing and CADTH queuing
schedule. October 8th, 2014
59. Sullivan SD, Craxi A, Alberti A, Giuliani G, DeCarli C,Wintfeld N
et al (2004) Cost effectiveness of peginterferon alpha-2a plus riba-
virin versus interferon alpha-2b plus ribavirin as initial therapy for
treatment-naive chronic hepatitis C. Pharmacoeconomics 22(4):
257–265
Eur J Clin Microbiol Infect Dis (2016) 35:597–609 609
